Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05060315 · ClinicalTrials.gov registry record
Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
A clinical trial, sponsored by United Therapeutics.
- Terminated
- Registry status
- 9
- Enrollment target
NCT05060315 is a clinical trial that was terminated before completion, run by United Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT05060315 was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- 9 participants
- Enrollment target
Study Summary
To observe and assess drug administration activities, time spent on drug administration activities, and patient-reported outcomes (PROs) including quality of life, treatment satisfaction, and patient perception of devices related to use of United Therapeutics Corporation (UTC)-developed next-generation infusion pumps to administer Remodulin in patients with Pulmonary Arterial Hypertension (PAH).
Interventions
- COMBINATION_PRODUCT Remunity Pump for Remodulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-07-05 |
| Est. Completion | 2024-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05060315
The ClinicalTrials.gov registry entry for NCT05060315 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Remunity Pump for Remodulin is the first listed.
NCT05060315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05060315 about?
NCT05060315 is a clinical study titled "Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin". To observe and assess drug administration activities, time spent on drug administration activities, and patient-reported outcomes (PROs) including quality of life, treatment satisfaction, and patient perception of devices related to use of United Therapeutics Corporation (UTC)-developed next-generat...
What is the current status of trial NCT05060315?
This trial is currently terminated. The enrollment target is 9 participants. The study started on 2023-07-05. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT05060315?
The interventions under investigation include: Remunity Pump for Remodulin (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05060315?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.